Back to search results

IRIS-CKD Program for Chronic Kidney Disease Screening in Diabetes

This study, called IRIS-CKD, is looking for adults with type 2 diabetes (T2D) who haven't had recent screening for chronic kidney disease (CKD). The goal is to find the best way to help people get screened for CKD, which is important for their health. You would receive educational materials about CKD screening. Participants will be randomly assigned to either receive a home kit for CKD screening or a standard lab order. The researchers will compare how well each method encourages people to get screened. The study aims to see if these approaches improve the number of people getting recommended CKD screening within 3 months. The current status of this study is unclear.

Study design
This interventional study plans to enroll 750 participants. It compares two different methods for encouraging CKD screening: a home kit versus a standard lab order.
What's involved
You would receive educational materials and a message about your lab results. You will complete approximately 3 months of follow-up.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for approximately 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06906627

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Recruiting
NAAges 18+Interventional
Duke University
~750 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:(IRIS-CKD Screening Program): Home Kit(IRIS-CKD Screening Program): Standard Lab Order

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
CKD Screening Lab Opportunity Score
Measured over 3 months

Conditions

Chronic Kidney Disease(CKD)
Type 2 DM
Type 2 Diabetes Mellitus (T2DM)

Explore related trials

Chronic Kidney DiseaseType 2 Diabetes Mellitus

Where it's being run

7 sites across 6 states
North Carolina2
Alabama1
Florida1
Michigan1
Minnesota1
Texas1

Study leadership

  • Neha Pagidipati, MD · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Gretchen Sanders, MSN
[email protected]
919 6687829
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults with type 2 diabetes (T2D)
Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).
Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR

What this trial measures

  • CKD Screening Lab Opportunity Score3 months

    Opportunity score of completion of missing guideline-recommended screening for CKD (eGFR and/or UACR) at 3 months. The opportunity score will be calculated as the ratio of the number of missing labs measured by month 3 divided by the number of missing labs at baseline.